



1. Mayo Clinic Laboratories utilizes the Meridian BreathID® qualitative spectrophotometry for analysis; with the Breath Test Kit, IDkit Hp™ Two. This system is indicated for use in adult patients and pediatric patients ages 3-17 years old. Safety and effectiveness has not been assessed in children below the age of 3 years. False positive results may occur in patients less than 6 years of age.
2. Consider HELIS / *Helicobacter pylori* Culture with Antimicrobial Susceptibilities, *Varies* or if not possible, HPRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Tissue.
3. Proton pump inhibitors should be avoided for 2 weeks prior to testing; antibiotics and bismuth containing products should be avoided for 4 weeks prior to testing. H2RAs and antacids do not affect results.
4. HPFRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces has equivalent accuracy to fecal antigen testing for *H pylori* detection and predicts clarithromycin susceptibility or resistance in *H pylori* if detected. Although, fecal antigen testing is available elsewhere, Mayo Clinic providers prefer and recommend the use of molecular testing for the detection of *H pylori*.
5. Consider HPFRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces or HPRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Tissue to assess for clarithromycin susceptibility if HELIS / *Helicobacter pylori* Culture with Antimicrobial Susceptibilities, *Varies* is not done.
6. Testing should be performed at least 4 weeks after completion of antibiotic therapy and after PPI therapy has been withheld for 2 weeks.
7. Consider HPFRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces to assess for clarithromycin susceptibility.